GeoVax Enhances Manufacturing Capabilities with Landmark Commercial License Agreement
Vaccines and immunotherapies company, GeoVax Labs, Inc., (Nasdaq: GOVX) will enhance its manufacturing capabilities following the signing of a landmark commercial license agreement with ProBioGen. The partnership will give GeoVax access to ProBioGen’s groundbreaking AGE1.CR.pIX® suspension cell line, enabling GeoVax to enhance the manufacturing capabilities of its entire Modified Vaccinia Ankara (MVA) based vaccine portfolio.
David Dodd, Chairman & CEO of GeoVax, said, “The AGE1.CR.pIX suspension Cell Line is a game-changer for our vaccine production, allowing us to streamline our manufacturing processes while maintaining the highest quality standards. This partnership with ProBioGen aligns perfectly with GeoVax’s mission of developing safe and effective vaccines to protect public health.”
Financial terms of the agreement were not disclosed.
ProBioGen’s AGE1.CR.pIX suspension cell line is an innovative and proven platform that enables high-yield and scalable production, ensuring efficient manufacturing processes, cost efficiency and increased productivity.
By leveraging this modern production technology, GeoVax aims to accelerate the manufacturing of its entire vaccine pipeline, reinforcing the company’s strong commitment to improving global access to life-saving vaccines.
Dr. Volker Sandig, CSO of ProBioGen, said, “We believe this partnership will significantly contribute to GeoVax’s ability to accelerate vaccine production and distribution, ultimately benefiting communities worldwide.”
About GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.